Human Anti-Lipopolysaccharide IgG+IgM

Your intestinal wall is supposed to keep the trillions of bacteria living in your gut from spilling into your bloodstream. When that barrier weakens, pieces of bacteria slip through, and your immune system answers by producing antibodies against them. This test measures those antibodies in your blood.

Tracking them offers an early, exploratory window into whether bacterial material is reaching your circulation and stirring up your immune system. This is a research-stage marker without standardized cutoffs, so a single number means little on its own. A baseline now gives you something to compare against as the science matures.

What This Test Actually Measures

The antibodies measured here are anti-LPS antibodies (immune proteins directed against lipopolysaccharide, a large molecule that coats the outer surface of many gut bacteria). Lipopolysaccharide is also called endotoxin because it can trigger strong inflammation when it enters the bloodstream. This test looks at two antibody types together: IgM, which your body makes early and broadly against new bacterial encounters, and IgG, which reflects longer-term immune memory and repeated exposure.

Unlike a test that tries to catch the bacterial molecule itself, this one measures your body's antibody response to it. That distinction matters. Circulating endotoxin is cleared from the blood very quickly, with animal studies pointing to a half-life of only a few minutes, making it nearly impossible to catch reliably, while antibodies linger and give a steadier readout of ongoing exposure.

Why It Points to a Leaky Gut Barrier

The gut is by far the largest source of endotoxin in the body, because it is packed with the kind of bacteria that carry lipopolysaccharide on their surface. When the intestinal barrier is intact, very little of that material crosses into the blood. When the barrier is weakened, more crosses, and sustained exposure can push antibody levels up over time.

This link shows up in people with signs of gut barrier trouble. In blood samples that also carried antibodies seen in inflammatory bowel conditions, elevated anti-LPS antibodies were about three times as common as in healthy samples (roughly 30 to 33 percent versus 9 to 12 percent). Higher anti-LPS antibodies have also tracked with antibodies against intestinal barrier proteins, consistent with a more permeable gut lining.

Higher Is Not Always Worse, and Lower Is Not Always Better

This is not a simple good-number, bad-number marker. A high level can mean chronic bacterial leakage across a damaged gut wall, which studies link to inflammation and higher disease risk. But a high level can also mean protective immunity built from past bacterial exposure, which in certain gut infections is associated with lower risk of getting sick. A low level is equally ambiguous: it can mean limited exposure, or it can mean your body is failing to make enough antibodies, as happens in some immune deficiencies. Read this number as an exposure and immune-response indicator, not a verdict, and always alongside the specific antibody type and your clinical situation.

Liver Cancer Risk

The strongest chronic-disease signal for this specific antibody comes from liver cancer research. In a study pooling 12 large groups of adults followed over time (867 people who later developed liver cancer matched to 867 who did not), higher anti-LPS IgG was associated with roughly 20 percent higher liver cancer risk for each doubling of the antibody level. The researchers interpreted this as a sign of gut barrier breakdown driving long-term immune activation.

A separate Finnish study pointed the same direction using a related but different antibody type, anti-LPS IgA, which was linked to about 2.4 times the liver cancer risk and an even stronger signal for the most common form of the disease. Not every liver finding lines up, though: in fatty liver disease, endotoxin-core IgG did not separate the more aggressive form from the milder one and did not track with scarring, so this marker is not a substitute for direct liver assessment.

Inflammation, Metabolic, and Autoimmune Conditions

Across chronic conditions, the pattern is real but mixed. In people with type 1 diabetes, those with metabolic syndrome tended to have lower endotoxin-core IgM, while endotoxin-core IgG tracked with hs-CRP (high-sensitivity C-reactive protein, a general marker of low-grade inflammation). In first-diagnosed atrial fibrillation, a shifted balance between IgG and IgM endotoxin antibodies was read as a sign of long-standing endotoxin exposure.

In rheumatoid arthritis, endotoxin-core IgM and IgA ran high, yet one anti-LPS IgG measure actually moved in the opposite direction from pain and disease activity, a reminder that more antibody does not automatically mean worse disease. In young people, endotoxin-core IgG tracked with visceral fat (the deep abdominal fat around organs) but not with broader metabolic problems, which circulating endotoxin itself predicted more strongly.

Protection Against Gut Infections

In specific enteric infections, having these antibodies before exposure can be genuinely protective, though the antibodies studied are usually aimed at one pathogen's version of lipopolysaccharide. Among 242 household contacts of cholera patients, those who already carried plasma antibodies to the cholera bacterium's surface sugar were less likely to become infected, and a specific memory-cell response was tied to a 44 percent reduction in infection risk.

For Shigella, serum IgG against the bacterium's lipopolysaccharide reached measurable protection thresholds, with a high titer in adults predicting about 74 percent vaccine efficacy. The picture is not clean, though. A vaccine challenge study that raised these antibodies failed to prevent disease overall, and a proposed protective IgG cutoff correctly cleared only about 33 out of every 100 people who were actually protected, meaning the level alone was an unreliable guarantee.

Use in Diagnosing Acute Infection

The most established clinical use of anti-LPS antibody testing is diagnosing certain acute infections, using pathogen-specific versions of the assay. In typhoid fever, anti-LPS antibodies correctly identified around 94 to 96 out of 100 cases when compared against healthy people, and combining anti-LPS with a second bacterial target held specificity near 95 percent. Against other fevers, performance was weaker and more variable, so the test works best when a specific infection is already suspected.

In acute leptospirosis, an anti-LPS IgM test caught cases far earlier than the traditional methods, correctly flagging about 99 out of 100 cases on admission, when culture caught only around 28 and a single conventional antibody test caught around 14. What the antibody adds is a fast read on your immune response when direct detection of the organism is still negative.

When Results Can Be Misleading

The single biggest caveat is that different labs can report very different numbers for the same sample. Lipopolysaccharide is not one molecule but a whole family of chemically different versions across bacterial species, and assays vary in design, calibration, and cutoff. In one multi-center antibody standardization effort, positivity cutoffs ranged from 7 to 90 units for IgG and 10 to 138 units for IgM. Newer automated platforms are far tighter, but the takeaway holds: compare results only within the same lab and method.

• Corticosteroids: prior steroid therapy has been linked to lower levels of both endotoxin-core IgG and IgM, so a result taken while you are on steroids can understate your true exposure without meaning anything about your gut.
• Age and blood type: IgM antibody signals tend to decline with age while IgG changes less, and blood type correlates with several antibody patterns, so unmatched comparisons can differ before any disease enters the picture.
• Immune complexes: these assays measure free antibody, so antibody already bound up with its target may go undetected and make a level look lower than it really is.

Why One Reading Is Not Enough

Because both your biology and the assay carry real variability, a trajectory tells you far more than any single value. Healthy people commonly carry measurable anti-LPS antibodies to begin with. In one survey of 1,612 blood donors, about 17 percent had high concentrations without being ill, so a lone positive is not inherently a problem.

The useful signal is change over time in your own baseline. Get a first reading, retest in 3 to 6 months if you are actively working on gut health, then at least once a year, always at the same lab using the same method. Watching the direction of travel is what separates a meaningful shift from lab-to-lab noise.

What to Do With an Out-of-Pattern Result

One unexpected value is a prompt to investigate, not to act. If a high level persists on a repeat draw and sits alongside elevated hs-CRP or ongoing gut symptoms, that combination is worth a fuller barrier workup, which might include LBP (lipopolysaccharide-binding protein), sCD14 (a soluble immune co-receptor for endotoxin), antibodies to gut barrier proteins, and stool calprotectin, ideally with a gastroenterologist. A persistently low level in someone with a history of frequent infections points in a different direction: checking your total IgG, IgA, and IgM helps rule out an underlying immune deficiency. In either case, this marker is one piece of a larger pattern, never a standalone answer.